Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14932795 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL24337161 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL19540775 | 0.78 | CES2 (0.48) | CES2CES1HDAC8HDAC6LMNA | |
| SCHEMBL21232394 | 0.75 | EPHX1 (0.42) | CES2CES1HDAC8HDAC6LMNA | |
| SCHEMBL599277 | 0.74 | CES2 (0.55) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL29333109 | 0.74 | CES2 (0.55) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL29333093 | 0.74 | CES2 (0.55) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL28425729 | 0.74 | CES2 (0.55) | CES2CES1HDAC8HDAC6EPHX1 | |
| SCHEMBL2769783 | 0.72 | DPP7 (0.44) | LMNAEPHX1SMN1; SMN2ALDH1A1 | |
| SCHEMBL784986 | 0.72 | CYP2D6 (0.44) | CES2CES1HDAC8HDAC6EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| EP-1833805-B1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP ZOO (PL) | 2010-02-10 | — | — | EP | disclosed |
| US-7312338-B2 | 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-12-25 | — | — | US | disclosed |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | ADAMED SP. Z O.O. (PL) | 2007-09-20 | — | — | US | disclosed |
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | ADAMED, SP. Z.O.O. (PL) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088061-A1 | New 3-phenylpropionic acid derivatives | PPARA, PPARD, PPARG | CES2 1286/4885CES1 302/4885HDAC8 1784/4885 |
| US-20070219259-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES | PPARA, PPARD, PPARG | CES2 1198/4885CES1 288/4885HDAC8 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.